TY - BOOK ID - 133454295 TI - Virus-Like Particle Vaccines AU - Bachmann, Martin F AU - Vogel, Monique PY - 2020 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Humanities KW - Social interaction KW - virus-like particle KW - influenza A(H1N1)pdm09 KW - vaccination KW - pregnant women KW - antibody titers KW - norovirus KW - VLP KW - vaccine KW - genotype KW - pre-existing immunity KW - cross-reactivity KW - blocking antibodies KW - original antigenic sin (OAS) KW - HPVs KW - vaccines KW - virus-like particles (VLPs) KW - minor capsid protein (L2) KW - HCMV KW - cytomegalovirus KW - nanoparticle KW - immune response KW - Sudan virus KW - mice KW - horse KW - purified IgG KW - long-lived plasma cells KW - antibodies KW - multivalency KW - virus-like particles KW - antigenic analysis KW - epitope characterization KW - hepatitis E vaccine KW - serological evaluation KW - virion-like epitopes KW - well-characterized vaccines KW - hepatitis B virus KW - surface (envelope) antigen KW - sub-viral particle KW - capsid KW - antigen display KW - platform KW - viral quantification KW - NTA KW - flow virometry KW - SRFM KW - cryo-TEM KW - SEM KW - plant virus KW - virus-like KW - vaccine platform KW - epitope KW - antigen KW - cat allergy KW - Fel d 1 KW - HypoCat™ KW - IL-13 KW - interleukin-13 KW - Tfh cells KW - cancer KW - immunotherapy KW - H7N9 KW - pandemic influenza A KW - avian flu KW - IAV KW - VLP vaccine KW - n/a UR - https://www.unicat.be/uniCat?func=search&query=sysid:133454295 AB - The structure, uniformity, stability, and functions of virus-like particles (VLPs) have encouraged scientists to utilize them as a unique tool in various applications in biomedical fields. Their interaction with the innate immune system is of major importance for the adaptive immune response they induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of two major characteristics: size and surface geometry. VLP-based vaccines against hepatitis B, human papilloma, malaria, and hepatitis E have been developed and are available in many countries around the world. Given the inherent immunogenicity of VLPs, they render themselves ideal for the development of new vaccines against infectious diseases as well as noncommunicable diseases, such as chronic inflammation or cancer. This Special Issue is designed to provide an up-to-date view of the latest progress in the development of VLP-based prophylactic and therapeutic vaccines and technologies for their generation. ER -